• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    5/31/24 4:32:51 PM ET
    $ADAG
    $ATRA
    $BGXX
    $CLDI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADAG alert in real time by email

    Gainers

    • Liquidia (NASDAQ:LQDA) stock rose 12.7% to $14.5 during Friday's after-market session. The market value of their outstanding shares is at $1.1 billion.
    • Adagene (NASDAQ:ADAG) shares moved upwards by 10.67% to $2.8. The company's market cap stands at $123.6 million.
    • Atara Biotherapeutics (NASDAQ:ATRA) stock moved upwards by 6.95% to $0.6. The market value of their outstanding shares is at $72.2 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) shares increased by 6.64% to $1.12. The company's market cap stands at $21.3 million.
    • IGC Pharma (AMEX:IGC) stock increased by 5.95% to $0.52. The company's market cap stands at $38.8 million.
    • Calidi Biotherapeutics (AMEX:CLDI) shares increased by 5.26% to $0.2. The company's market cap stands at $10.1 million.

    Losers

    • Portage Biotech (NASDAQ:PRTG) shares declined by 14.1% to $0.41 during Friday's after-market session. The company's market cap stands at $8.1 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares fell 10.09% to $0.28. The market value of their outstanding shares is at $15.4 million.
    • Bright Green (NASDAQ:BGXX) shares decreased by 9.03% to $0.25. The market value of their outstanding shares is at $47.9 million.
    • Onconetix (NASDAQ:ONCO) shares decreased by 6.65% to $0.19. The market value of their outstanding shares is at $4.3 million.
    • Eyenovia (NASDAQ:EYEN) shares fell 6.28% to $0.76. The company's market cap stands at $40.7 million.
    • CareCloud (NASDAQ:CCLDP) stock fell 5.82% to $10.69. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAG
    $ATRA
    $BGXX
    $CLDI

    CompanyDatePrice TargetRatingAnalyst
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    Adagene Inc.
    $ADAG
    11/24/2025$9.00Buy
    Guggenheim
    Liquidia Corporation
    $LQDA
    10/20/2025$31.00Overweight
    Wells Fargo
    Liquidia Corporation
    $LQDA
    8/15/2025$43.00Buy
    Jefferies
    Adagene Inc.
    $ADAG
    8/6/2025$7.00Outperform
    Leerink Partners
    Liquidia Corporation
    $LQDA
    5/19/2025$13.00Perform → Underperform
    Oppenheimer
    Adagene Inc.
    $ADAG
    1/31/2025Overweight → Equal-Weight
    Morgan Stanley
    Liquidia Corporation
    $LQDA
    12/20/2024$20.00Overweight
    Wells Fargo
    More analyst ratings

    $ADAG
    $ATRA
    $BGXX
    $CLDI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Adagene with a new price target

    Guggenheim initiated coverage of Adagene with a rating of Buy and set a new price target of $9.00

    11/24/25 8:15:55 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Liquidia Technologies with a new price target

    Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $31.00

    10/20/25 8:01:49 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ATRA
    $BGXX
    $CLDI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Jackson Andrew C. bought $5,000 worth of shares (2,500 units at $2.00) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:36 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Poma Eric E bought $50,000 worth of shares (25,000 units at $2.00) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:39 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Leftwich Scott bought $250,000 worth of shares (125,000 units at $2.00), increasing direct ownership by 2,212% to 130,650 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:37 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $ATRA
    $BGXX
    $CLDI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

    SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug will be highlighted in two poster presentations at this year's AACR Meeting, taking place April 17-22 in San Diego, CA. The following abstracts have been selected for presentation at AACR 2026: Title: Ph1b evaluation of ADG126 (muzastotug, an anti-CTLA-4 masking antibody) pembrolizumab (Pembro) IO doublet in combination with fruquintinib (Fruq) in advanced and metastatic microsatellite stable colorectal cancerSession Title: Phase I Clinical Trials in Pr

    3/17/26 4:35:00 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

    Atara delivers significant operational efficiencies and extends cash runway through year-end 2026 A Type A meeting has been scheduled between Pierre Fabre Pharmaceuticals and the FDA Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2025 and business updates. "We continue to focus on streamlining our costs and liabilities, allowing us to be a nimbler, fit for purpose organization," said Cokey Nguyen Ph.D., President and Chief Executi

    3/16/26 4:05:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Complete Response Letter (CRL) to the Biologics License Application (BLA) for tabelecleucel (tab-cel) held by our partner Pierre Fabre Pharmaceuticals. Pierre Fabre Pharmaceuticals, with Atara's support, will meet with the agency to collaboratively address the points from the CRL and enable a resubmission with the additional efficacy data

    3/12/26 8:05:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $ATRA
    $BGXX
    $CLDI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Panacea Innovation Ltd

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    3/19/26 4:30:10 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Adagene Inc.

    3 - Adagene Inc. (0001818838) (Issuer)

    3/18/26 9:05:24 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Adagene Inc.

    3 - Adagene Inc. (0001818838) (Issuer)

    3/18/26 9:04:43 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ATRA
    $BGXX
    $CLDI
    SEC Filings

    View All

    SEC Form 10-KT filed by IGC Pharma Inc.

    10-KT - IGC Pharma, Inc. (0001326205) (Filer)

    3/18/26 4:02:27 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Onconetix Inc.

    PRE 14A - Onconetix, Inc. (0001782107) (Filer)

    3/18/26 7:55:08 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Atara Biotherapeutics Inc.

    S-3 - Atara Biotherapeutics, Inc. (0001604464) (Filer)

    3/17/26 4:17:25 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $ATRA
    $BGXX
    $CLDI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MYDCOMBI issued to EYENOVIA INC.

    Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/8/23 1:05:04 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

    Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

    11/18/21 2:49:33 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ATRA
    $BGXX
    $CLDI
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

    Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell amplifiers.Calidi expects to present proof of concept data demonstrating the applicability of the RedTail platform in non-oncology indications. SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) --

    1/28/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

    SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor. "Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, and ADG126 to mask the CTLA-4 binder (ADG116) until it reaches the tumor microenvironment aiming for an enhanced efficacy and reduced toxicity profile. The design of these antibodies may allow a broad

    9/3/25 9:05:21 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group

    LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced several key developments in support of its digital asset capital strategy. Avenue Capital Group, now the Company's largest common stockholder, has agreed to amend Eyenovia's senior secured debt to further support the Company as it builds its HYPE treasury and reserve of the HYPE token. Pursuant to the terms of the amendment, the maturity date of the debt has been extended from November 1, 2025 to

    6/18/25 8:32:42 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ATRA
    $BGXX
    $CLDI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

    SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

    12/4/24 4:12:20 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 6:10:20 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eyenovia Inc.

    SC 13G/A - EYENOVIA, INC. (0001682639) (Subject)

    11/14/24 5:08:44 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ATRA
    $BGXX
    $CLDI
    Financials

    Live finance-specific insights

    View All

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient starts to dateCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on November 3, 2025, to review financ

    11/3/25 6:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

    MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a b

    10/27/25 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care